Related references
Note: Only part of the references are listed.Deficient RPS19 protein production induces cell cycle arrest in erythroid progenitor cells
Madoka Kuramitsu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34(+) cells
Laure A. Moutouh-de Parseval et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Benjamin L. Ebert et al.
NATURE (2008)
Lentiviral-Mediated HoxB4 Expression in Human Embryonic Stem Cells Initiates Early Hematopoiesis in a Dose-Dependent Manner but Does Not Promote Myeloid Differentiation
Christian Unger et al.
STEM CELLS (2008)
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome
Benjamin L. Ebert et al.
PLOS MEDICINE (2008)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza et al.
BLOOD (2008)
Gene expression profiling of CD34+ cells in patients with the 5q-syndrome
Jacqueline Boultwood et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Isochromosome (X)(p10) in hematologic disorders: FISH study of 14 new cases show three types of centromere signal patterns
Adewale Adeyinka et al.
CANCER GENETICS AND CYTOGENETICS (2007)
Common deleted genes in the 5q-syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice
S. Lehmann et al.
LEUKEMIA (2007)
Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders
John M. Joslin et al.
BLOOD (2007)
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Andrea Pellagatti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Role for the PP2A/B56δ phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis
Seth S. Margolis et al.
CELL (2006)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly
AK Gandhi et al.
LEUKEMIA RESEARCH (2006)
Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution
P Bernasconi et al.
LEUKEMIA (2005)
A structural basis for 14-3-3σ functional specificity
EW Wilker et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
Fostriecin: Chemistry and biology
DS Lewy et al.
CURRENT MEDICINAL CHEMISTRY (2002)
Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome
J Boultwood et al.
BLOOD (2002)
B56-associated protein phosphatase 2A is required for survival and protects from apoptosis in Drosophila melanogaster
XH Li et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding
PR Graves et al.
ONCOGENE (2001)
Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling
V Janssens et al.
BIOCHEMICAL JOURNAL (2001)
Share Paper
